Preliminary research completed, China has two more anti-coronavirus drugs entering the clinic

Since the outbreak of the new crown pneumonia, China has continuously researched and explored effective treatment methods in the medical treatment work, and has started the research and development of anti-new crown virus drugs

"At present, the two anti-coronavirus drugs have completed preclinical studies, and have entered the clinical research phase in many countries.

Oral anti-coronavirus drug candidate VV116 approved for clinical trials in Uzbekistan

VV116 is an oral nucleoside anti-coronavirus candidate drug jointly developed by many domestic scientific research institutions, including Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Wuhan Institute of Virology, Chinese Academy of Sciences, and Xinjiang Institute of Physics and Chemistry, Chinese Academy of Sciences

Preclinical pharmacodynamic studies have shown that VV116 has significant inhibitory activity against the original virus strains and mutant strains of new coronavirus in vitro, such as Delta virus, and is expected to become a variety of anti-epidemic methods including vaccines and antibody drugs.

The research team of researcher Shen Jingshan from Shanghai Institute of Materia Medica, Chinese Academy of Sciences and cooperating scientific research institutes found through experiments on adenovirus mouse models that oral administration of VV116 can reduce the virus titer below the detection limit, and can significantly improve the pathological changes in the lung tissue of experimental model animals

Researcher Shen Jingshan introduced that at present, VV116 drug candidates have fully completed preclinical studies.

Innovative drug FB2001 has undergone phase I clinical research in the United States

Another anti-new coronavirus drug candidate, FB2001, is also under intense research

Researcher Liu Hong, the head of the research group, told reporters that they are mainly conducting innovative drug research on a very important target in the replication cycle of the new coronavirus-3CL proteolytic enzyme.

The candidate drug was approved by the U.

The drug has been administered in 3 dose groups of 5 mg, 15 mg, and 30 mg.

It is understood that for the research and development of anti-coronavirus drugs, the Shanghai Institute of Materia Medica, Chinese Academy of Sciences has achieved good results in the construction of screening systems, virtual screening, high-throughput screening, the discovery of lead compounds, and the subsequent development of small molecule drug candidates.